Most Read Articles
Roshini Claire Anthony, 12 Jun 2019

Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving 2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.

Audrey Abella, 09 Jul 2019
A fixed single‐dose of netupitant 300 mg plus palonosetron 0.50 mg (NEPA) was better than palonosetron and aprepitant in preventing acute and delayed* chemotherapy-induced nausea and vomiting (CINV) following multiple chemotherapy cycles, according to the results of two phase III trials.

Early menopause linked to reduced walking speed

19 Jun 2019

Women who have entered menopause before the age of 40 years happen to walk much slower compared with those who have reported later menopause, as reported in a recent study from Canada.

The study used data from the Canadian Longitudinal Study on Aging and included 9,920 women who reported to have entered menopause. Age at natural menopause (ANM) was categorized as follows: <40 years (premature), 40–44 years (early), 45–49 years, 50–54 years and >54 years. None of the participants had a hysterectomy before menopause.

Mean ANM was 49.8 years, with 3.8 percent of women reporting premature menopause and 8.7 percent reporting early menopause. Women with earlier ANM were more likely to have lower education, be currently smoking, and be underweight, overweight or obese. Furthermore, use of hormone therapy (HT) was more prevalent in women with earlier ANM.

Researchers measured gait speed using the timed 4-minute walk test and gait strength using a wireless grip dynamometer. Average gait speed of the cohort was 0.98 m/s, while average grip strength was 26.6 kg.

Gait speed was notably lower by a mean of 0.054 m/s among women with premature menopause than among those who had ANM of 50–54 years. On further analysis, the observed difference was attenuated to 0.032 m/s.

Grip strength, on the other hand, was not associated with ANM.

The findings highlight the need to consider women with premature menopause as a clinical priority group for promotion of healthy ageing initiatives (eg, physical activity interventions and nutritional supplementation) that boost physical function, the researchers said.

More studies including early life social and reproductive exposures are needed in order to determine whether social and biological pathways modify the association between ANM and physical function in populations with different socioeconomic backgrounds, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 12 Jun 2019

Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving 2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.

Audrey Abella, 09 Jul 2019
A fixed single‐dose of netupitant 300 mg plus palonosetron 0.50 mg (NEPA) was better than palonosetron and aprepitant in preventing acute and delayed* chemotherapy-induced nausea and vomiting (CINV) following multiple chemotherapy cycles, according to the results of two phase III trials.